Personalized <i>Clostridioides difficile</i> engraftment risk prediction and probiotic therapy assessment in the human gut.

ABSTRACT: Clostridioides difficile colonizes up to 30-40% of community-dwelling adults without causing disease. C. difficile infections (CDIs) are the leading cause of antibiotic-associated diarrhea in the U.S. and typically develop in individuals following disruption of the gut microbiota due to antibiotic or chemotherapy treatments. Further treatment of CDI with antibiotics is not always effective and can lead to antibiotic resistance and recurrent infections (rCDI). The most effective treatment for rCDI is the reestablishment of an intact microbiota via fecal microbiota transplants (FMTs). However, the success of FMTs has been difficult to generalize because the microbial interactions that prevent engraftment and facilitate the successful clearance of C. difficile are still o

SUBMITTER: Carr A 

PROVIDER: S-EPMC10168307 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature